A Systematic Review of Metachromatic Leukodystrophy Newborn Screening: Transitioning from Pilot Studies to the Real World.
8 affiliations
- 1Department of Pediatrics, Children's Hospital Aarau (KSA), 5000 Aarau, Switzerland.
- 2University Children's Hospital Zurich, 8008 Zurich, Switzerland.
- 3Faculty of Medicine, University of Basel, 4056 Basel, Switzerland.
- 4Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
- 5Division of Pediatric Blood and Marrow Transplantation and Cellular Therapy, University of Minnesota, Minneapolis, MN 55454, USA.
- 6Pediatric Neurology, Developmental Pediatrics and Neurorehabilitation of Northwestern Switzerland, University Children's Hospital Basel (UKBB), Basel and Children's Hospital Aarau (KSA), 5000 Aarau, Switzerland.
- 7Newborn Screening Ontario, Ottawa, ON K1H 8L1, Canada.
- 8Faculty of Medicine, University of Zurich, 8032 Zurich, Switzerland.
Abstract
Metachromatic leukodystrophy (MLD) is a rare lysosomal storage disorder causing progressive neurodegeneration through central and peripheral demyelination, leading to premature death. Recent advances in ex vivo lentiviral gene therapy have developed a potentially curative treatment approach for pre-symptomatic infants with early-onset MLD. This systematic review evaluates the current evidence regarding newborn screening (NBS) for MLD, including screening methodologies, diagnostic pathways, and implementation challenges, using the Swiss healthcare system as an illustrative example. A literature search using keywords MLD and NBS was conducted across five databases on 29 September 2025 and updated on 21 September 2026, along with contacting leading experts of the field up to 1 July 2026, resulting in the inclusion of 27 publications and six conference papers. Multi-tiered screening algorithms combining sulfatide species quantification, second-tier enzyme activity measurement, and genetic confirmation testing can reliably identify MLD-affected infants while reducing false-positive results. Pilot studies and early national implementation programs have confirmed the feasibility of population-based MLD NBS. We consider Switzerland well positioned to integrate MLD into its centralized national NBS program. Several factors, including achieving cost-effectiveness, subtype prediction, and management of uncertain cases, require thorough consideration and represent potentially universal barriers to widespread adoption of MLD NBS beyond pilot programs around the world.
Related
- Newborn screening for beta-ketothiolase deficiency: evidence from a systematic review
- Newborn Screening for X-Linked Adrenoleukodystrophy: A Systematic Literature Review.
- Cost-effectiveness of newborn screening for phenylketonuria and congenital hypothyroidism in Hubei, China.
- Incidental maternal glutaric aciduria type I detection through newborn screening: A case report
- The Current Perspective, Ethical Considerations, and a Position Statement on Expanded Newborn Screening from the College of Paediatrics, Academy of Medicine of Malaysia.
BibTeX
@article{waser2026systematic,
title = {{A Systematic Review of Metachromatic Leukodystrophy Newborn Screening: Transitioning from Pilot Studies to the Real World.}},
author = {Samuel Waser and Simone Kistler and Laura A Adang and Paul J Orchard and Alexandre N Datta and Neal Sondheimer and Henrik Köhler and Daniel Drozdov},
journal = {International journal of neonatal screening},
year = {2026},
month = oct,
doi = {10.3390/ijns12040086},
url = {https://europepmc.org/article/MED/42924763},
note = {CC BY},
}
RIS
TY - JOUR
TI - A Systematic Review of Metachromatic Leukodystrophy Newborn Screening: Transitioning from Pilot Studies to the Real World.
AU - Samuel Waser
AU - Simone Kistler
AU - Laura A Adang
AU - Paul J Orchard
AU - Alexandre N Datta
AU - Neal Sondheimer
AU - Henrik Köhler
AU - Daniel Drozdov
PY - 2026
DA - 2026/10/17
JO - International journal of neonatal screening
DO - 10.3390/ijns12040086
UR - https://europepmc.org/article/MED/42924763
AB - Metachromatic leukodystrophy (MLD) is a rare lysosomal storage disorder causing progressive neurodegeneration through central and peripheral demyelination, leading to premature death. Recent advances in ex vivo lentiviral gene therapy have developed a potentially curative treatment approach for pre-symptomatic infants with early-onset MLD. This systematic review evaluates the current evidence regarding newborn screening (NBS) for MLD, including screening methodologies, diagnostic pathways, and implementation challenges, using the Swiss healthcare system as an illustrative example. A literature search using keywords MLD and NBS was conducted across five databases on 29 September 2025 and updated on 21 September 2026, along with contacting leading experts of the field up to 1 July 2026, resulting in the inclusion of 27 publications and six conference papers. Multi-tiered screening algorithms combining sulfatide species quantification, second-tier enzyme activity measurement, and genetic confirmation testing can reliably identify MLD-affected infants while reducing false-positive results. Pilot studies and early national implementation programs have confirmed the feasibility of population-based MLD NBS. We consider Switzerland well positioned to integrate MLD into its centralized national NBS program. Several factors, including achieving cost-effectiveness, subtype prediction, and management of uncertain cases, require thorough consideration and represent potentially universal barriers to widespread adoption of MLD NBS beyond pilot programs around the world.
SN - 2409-515X
ER -